Michael Knauth, director of Neuroradiology, University Hospital of Goettingen, Goettingen, Germany, and president-elect of the German Society of Neuroradiology, presented at the ABCWIN seminar, Val d’Isère, France, the European evaluation data on the Separator 3D (Penumbra).
A new analysis from a two-year follow up of participants in the CREST (Carotid revascularization endarterectomy versus stenting) trial show that carotid artery stenting and carotid endarterectomy are equally effective at halting carotid restenosis in stroke prevention. Results of the analysis were detailed in a presentation at the American Stroke Association’s International Stroke Conference (%ew Orleans, USA, 1–3 February 2012).
Saruhan Çekirge, professor, Hacettepe University Hospitals, Ankara,Turkey, told delegates at the European Society of Minimally Invasive #eurological Therapy congress (ESMI#T) held in #ice, France, that the impact of flow diversion/modification on the endovascular treatment of aneurysms with an important branch originating from the aneurysm sac was a “revolutionary change”.
Covidien announced that the Solitaire FR Revascularization device has been approved for investigational use in the IMS III (Interventional management of stroke) trial. The Solitaire FR device was approved by the IMS III executive committee in the thrombectomy arm of the trial and was included in a recently approved amendment submitted to the US Food and Drug Administration (FDA).
The Food and Drug Administration (FDA) has given clearance to ev3 / Covidien for its Solitaire FR revascularisation device which is intended to restore blood flow to the brain in patients suffering acute ischaemic stroke by mechanically removing blood clots from blocked vessels.
An experimental device for removing blood clots in stroke patients dramatically outperformed the standard mechanical treatment, according to research presented on 3 February at a late breaking trial session by Jeffrey L Saver, Stroke Center director, University of California, Los Angeles, (UCLA), USA, at the American Stroke Association’s International Stroke Conference 2012.
Toshiba has announced that all new, and already installed, Aquilion One, Premium and Prime scanners, should be entitled to get the AIDR 3D algorithm to reduce radiation dose exposure an noise in imaging procedures without the need for substantial upgrade costs.
On 2 February, at the Late-Breaking Science Session at the International Stroke Conference, the results of the TREVO study (Thrombectomy revascularization of large vessel occlusions in acute ischaemic stroke) were presented. TREVO is one of the first prospective, multicentre clinical studies of clot-removing stent retriever technology. Sixty patients were enrolled by seven leading stroke centres in Europe.
Istvan Szikora, National Institute of Neurosciences, Neurointerventions, Hungary, spoke on behalf of the ESMINT Flow Diverter Bleeding Project contributors to tell delegates that a small, real world, unselected series analysis has shown that the characteristics determining delayed rupture of intracranial aneurysms when treated by flow diverters are aneurysm size and symptomatic clinical presentation.
Jean Raymond, François Guilbert, Daniel Roy and Alain Weill from the Department of Radiology, CHUM, &otre-Dame Hospital, Montreal, Canada, and Tim E Darsaut, University of Alberta Hospital, Mackenzie Health Sciences Centre, Department of Surgery, Division of &eurosurgery, Edmonton, Canada, spoke to NeuroNews about the hope, hype and hoopla surrounding flow diverters, and why the most important aspect of the FIAT trial is not the scientific knowledge gained but the protection of patients.
Adrian Ringelstein, Essen, Germany, presented the results of a study at the European Congress of Radiology (ECR) in Vienna, Austria, in March which showed a high aneurysm occlusion rate in the mid-term follow-up after treatment of complex aneurysms with flow diverters. The study also revealed a complication rate that was “not low”.
On 14 March, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) authorised the use of the recombinant tissue plasminogen activator (rt-PA) alteplase (Actilyse, Boehringer Ingelheim) for the thrombolytic treatment of acute ischaemic stroke up to 4.5 hours after symptom onset, and after prior exclusion of intracranial haemorrhage. Previously, alteplase was authorised for a 3 hour treatment window.
The risk of re-bleeding after intracranial hemorrhage did not increase when patients received early prophylaxis for venous thromboembolism (VTE), results of a retrospective review showed. Re-bleeding or hematoma expansion within 24 hours occurred in 5% to 6% of patients, irrespective of the timing of VTE prophylaxis.
Occluding the proximal carotid artery with a balloon may confer better protection against cerebral embolization than a distal filter device during carotid stenting, a randomized trial found. Compared with distal filter protection, proximal balloon occlusion significantly reduced the incidence of new ischemic lesions, according to Joachim Schofer, MD, from Hamburg University Cardiovascular Center in Hamburg, Germany, and colleagues.
A new study presented in March at the European Congress of Radiology (ECR) 2012 meeting in Vienna, Austria, indicates that mechanical intracranial thrombus extraction using the Trevo device (Concentric Medical/Stryker) is reasonably effective and has a reasonable morbidity and mortality rate in the treatment of acute ischaemic stroke. The results were also published in the journal Stroke, in March 2012.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos